How does IKPM's PE Ratio compare to its peers?

IKPM is good value based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (41x).

How does IKPM's PE Ratio compare vs other companies in the Asian Personal Products Industry?

IKPM is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the Asian Personal Products industry average (24.7x).

What is IKPM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IKPM's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of IKPM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

IKPM (IDR266) is trading above our estimate of [[fair value]] (IDR21.31)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

IKPM Stock Overview

Engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. More details

IKPM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	1/6

Risk Analysis

Interest payments are not well covered by earnings

Does not have a meaningful market cap (IDR448B)

My Notes

Capture your thoughts, links and company narrative

PT Ikapharmindo Putramas Tbk Competitors

Estee Gold Feet

IDX:EURO

Rp392.5b

Brigit Biofarmaka Technologi

IDX:OBAT

Rp357.0b

Kino Indonesia

IDX:KINO

Rp1.7t

Victoria Care Indonesia

IDX:VICI

Rp4.2t

Price History & Performance

Summary of share price highs, lows and changes for Ikapharmindo Putramas
Historical stock prices
Current Share Price	Rp266.00
52 Week High	Rp332.00
52 Week Low	Rp197.00
Beta	0
1 Month Change	9.02%
3 Month Change	-5.67%
1 Year Change	8.13%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	46.96%

Recent updates

Shareholder Returns

	IKPM	ID Personal Products	ID Market
7D	-3.6%	-1.7%	1.1%
1Y	8.1%	6.2%	5.8%

Return vs Industry: IKPM exceeded the ID Personal Products industry which returned 6.2% over the past year.

Return vs Market: IKPM exceeded the ID Market which returned 5.8% over the past year.

Price Volatility

Is IKPM's price volatile compared to industry and market?
IKPM volatility
IKPM Average Weekly Movement	3.6%
Personal Products Industry Average Movement	3.9%
Market Average Movement	5.7%
10% most volatile stocks in ID Market	13.4%
10% least volatile stocks in ID Market	2.6%

Stable Share Price: IKPM has not had significant price volatility in the past 3 months compared to the ID market.

Volatility Over Time: IKPM's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1978	1,054	. Kartono	www.ikapharmindo.com

PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing. The company offers prescription medicines in the areas of neurology, psychiatry, dermatology, nephrology, gastroenterology, cardiology, pulmonology, antibiotics, generics, and nutraceuticals; and over-the-counter drugs.

PT Ikapharmindo Putramas Tbk Fundamentals Summary

How do Ikapharmindo Putramas's earnings and revenue compare to its market cap?
IKPM fundamental statistics
Market cap	Rp448.12b
Earnings (TTM)	Rp11.93b
Revenue (TTM)	Rp424.89b

37.6x

P/E Ratio

1.1x

P/S Ratio

Is IKPM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IKPM income statement (TTM)
Revenue	Rp424.89b
Cost of Revenue	Rp233.56b
Gross Profit	Rp191.33b
Other Expenses	Rp179.40b
Earnings	Rp11.93b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	7.08
Gross Margin	45.03%
Net Profit Margin	2.81%
Debt/Equity Ratio	70.7%

How did IKPM perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

22%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/21 00:10
End of Day Share Price	2025/01/21 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Ikapharmindo Putramas Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution